Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan, Inc.    AGN

SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector newsTweets 

Allergan, Inc. : Allergan 3rd-Quarter Profit Edges Down; Weighs Options for Obesity Segment

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/30/2012 | 03:07pm CET
   By Tess Stynes 
 

Allergan Inc.'s (AGN) third-quarter earnings edged down slightly as the maker of Botox and medical devices posted more one-time items, masking continued sales growth for top drug Botox.

Since the end of the quarter, Allergan said it is exploring strategic options for its obesity intervention business, including among other things, a potential sale of the unit.

For the year, the company raised the lower end of its guidance and now expects per-share earnings of $4.17 and $4.19 on product sales of $5.7 billion to $5.8 billion. Its prior view was for per-share profit of $4.15 to $4.19 and product sales of $5.65 billion to $5.8 billion.

For the current quarter, Allergan forecast per-share earnings of $1.18 to $1.20 on revenue of $1.47 billion to $1.55 billion. Analysts polled by Thomson Reuters most recently expected $1.20 and $1.51 billion, respectively.

Chief Executive David E.I. Pyott in August had commented that the company is watching carefully for signs of economic vulnerability, but doesn't see a threat to long-term goals. Allergan's cosmetic medical products seem to appeal to people with greater economic means and purchasing power, providing some shelter from economic turmoil, he said at the time.

Allergan reported a profit of $249.4 million, down from $249.8 million a year earlier. On a per-share basis, earnings were up at 82 cents from 81 cents amid fewer shares outstanding. Excluding acquisition and restructuring related charges and other items, earnings were up at $1.06 from 92 cents.

Revenue increased 6.4% to $1.41 billion. Product net sales were up 6.1% to $1.39 billion, and were up 9.4% excluding currency impacts.

The company in August forecast per-share earnings of $1.02 to $1.04 on revenue of $1.37 billion to $1.45 billion.

Gross margin rose to 86.7% from 85.8% amid the increased revenue.

Sales of Botox, which is used as a medical treatment and wrinkle-fighting cosmetic tool, rose 8.8% to $431.6 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue-increased 8.1%, or roughly 11% excluding currency fluctuations.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN, INC.
03/24 GLOBAL GLAUCOMA THERAPEUTICS MARKET : Allergan, Merck, Novartis, Pfizer, Santen..
03/24 GLOBAL GASTROINTESTINAL DRUGS MARKET : Abbott Laboratories, Allergan, AstraZenec..
03/22 Global Inhalation & Nasal Spray Generic Drugs Market- Teva, Allergan PLC, Cip..
03/22 ALLERGAN : Announces Availability of RESTASIS MULTIDOSE™ (Cyclosporine Oph..
03/20 ALLERGAN : JUVÉDERM VOLLURE™ XC Approved by U.S. FDA for Correction of Fac..
03/17 ALLERGAN : Prevent Blindness and Allergan Work Together Through See America to P..
03/17 ALLERGAN : Editas partner on CRISPR tech in eye diseases
03/17 ALLERGAN : Lupin in fast lane with 5 launches in 15 days
03/16 ALLERGAN : Prevent Blindness and Allergan Work Together Through 'See America' to..
03/16 ALLERGAN : Dr. Anil Shah MD, FACS Offers Juvederm Volbella for Lip Fullness And ..
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 MANNKIND : A Head Pain Gain Or A Pocket-Book Drain?
2015 Tracking Dan Loeb's Third Point Portfolio - Q1 2015 Update
2015 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update
2015 Time Warner Is A Buy - Cramer's Lightning Round (5/21/15)
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Income Statement Evolution
More Financials
Managers
NameTitle
Ambrose Robert Douglas Bailey Chief Executive Officer
Maria Teresa Hilado Chief Financial Officer
Scott M. Whitcup Chief Scientific Officer & Executive VP-Research
Raymond H. Diradoorian Executive VP-Global Technical Operations
Joann Bradley Investor Relations Contact
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN, INC.13.00%0
JOHNSON & JOHNSON9.28%341 301
ROCHE HOLDING LTD.7.52%219 164
PFIZER INC.5.57%204 201
NOVARTIS AG-0.94%196 550
MERCK & CO., INC.7.49%173 740
More Results